Designed based on an in-depth understanding of incretin biology, tirzepatide can simultaneously activate GLP-1 and GIP receptors, thereby exerting synergistic effects that translate into superior outcomes in glycemic control, body weight management, and pancreatic -cell function preservation (19, 20)
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (marketed as Mounjaro) and chronic weight management (marketed as Zepbound)
The animal studies used both local application at the injury site and systemic administration (intraperitoneal and intragastric), with both routes showing significant effects
Learn More Zepbound vials Available via LillyDirect Medication cost billed by LillyDirect A once-weekly injectable GLP-1/GIP dual agonist indicated for the treatment of overweight and obesity
However, it should always be guided by lab data and professional oversight
JAMA 2015;314:68799.ArticlePubMed 15
